Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 799 results for "sll"

Forum Post: CLL Support Association Video appeal for volunteers
Macmillan Cancer Support

Forum Post: CLL Support Association Video appeal for volunteers

CLL, SLL, HCL For people affected by CLL (chronic lymphocytic leukaemia), SLL (small lymphocytic lymphoma), or HCL (hairy cell leukaemia) to get together, ask questions, share experiences and support each other. CLL Support Association Video ... Macmillan Cancer Support, 8 hours ago
[x]  

38 images for sll

Cancernetwork.com, 1 hour ago
Macmillan Cancer Support, 8 hours ago
Design MENA, 4 weeks ago
Contract Hire and Leasing.com, 1 month ago
MSN Canada, 1 month ago
Prolific North, 1 month ago
I Stock Analyst, 1 month ago
CIBSE, 1 month ago
Cancernetwork.com, 1 month ago
Columbus Dispatch, 1 month ago

Missing Carnarvon fisherman found

BERNIER ISLAND (Frame content direct link: https://maps.google.com.au/maps-q=Bernier Island, Western Australia&hl=en&sll=-31.968884,115.931338&sspn=1.936227,2.469177&oq=bernier Is&hnear=Bernier Island&t=m&z=9&output=embed.) A CARNARVON fisherman, ...
 NEWS.com.au1 week ago Bomb found in Bullsbrook landfill  NEWS.com.au3 weeks ago
Power Engineering

Heat Trace Cable

Chromalox announces the Series Long Line (SLL). Series Long Line heat trace is similar in construction to Chromalox's current self-regulating heat trace, making it compatible with their current accessory offering. This type of heat trace cable is ...
 Power Engineering1 week ago

Sierratel donates SLL 200 mln to fight Ebola outbreak

Add comment We welcome comments that add value to the discussion. We attempt to block comments that use offensive language or appear to be spam, and our editors frequently review the comments to ensure they are appropriate. If you see a comment ...
 Telecompaper1 week ago

Standard Life completes £390m Ignis acquisition

LONDON (ShareCast) - Standard Life (LSE: SL.L - news ) has completed the £390m purchase of Ignis Asset Management from insurance peer Phoenix Group . The deal, which has now received approval from the Financial Conduct Authority, was first ...
 Yahoo! UK and Ireland3 weeks ago
4 Traders

Pharmacyclics's sNDA for CLL and SLL drug receives FDA acceptance for filing

Pharmacyclics, Inc., a biopharmaceutical company, has received FDA acceptance for filing its supplemental new drug application, or sNDA, to support the review of IMBRUVICA in the treatment of patients with chronic lymphocytic leukemia, or CLL, and ...
 Individual.com1 month ago IMBRUVICA(r) (ibrutinib) Significantly Improves Progression Free Survival,  Finwin1 month ago Ibrutinib RESONATE(TM) Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma  Individual.com1 month ago FDA accepts Pharmacyclics' IMBRUVICA sNDA for review  News-Medical.Net1 month ago
[x]  

TG Therapeutics' Novel Combination of TG-1101 (Ublituximab) and TGR-1202 Demonstrates Compelling Early Activity and Safety Profile in Patients With Previously Treated High-Risk Chronic Lymphocytic Leu

100% of CLL/SLL patients had significant nodal reduction with either a normalization of or ≥80% reduction in Blood Lymphocyte Count4 of 5 CLL/SLL patients achieved a partial response at first assessment, including a patient relapsed from a prior ...
 Wall Street Select3 days ago TG THERAPEUTICS' : Novel Combination of TG-1101 (Ublituximab) and TGR-1202 Demonstrates Compelling Early Activity and Safety Profile in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) and Aggressive Lymphomas  4 Traders3 days ago TG Therapeutics' (TGTX) CEO Mike Weiss on Q2 2014 Results - Earnings Call Transcript  Seeking Alpha2 days ago
[x]  
European Pharmaceutical Manufacturer

FDA Approves Indications for Zydelig for Three Blood Cancers—CLL, FL, and SLL

The U.S. Food and Drug Administration has today approved Zydelig (idelalisib) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). The drug is to be used in combination with rituximab in patients for whom rituximab alone ...
 Oncology Times22 hours ago FDA approves Zydelig for CLL, SLL, follicular lymphoma  Orthopedics Today1 day ago Zydelig gets FDA approval for treatment of patients with three types of blood cancers  News-Medical.Net17 hours ago Idelalisib (Zydelig) Approved for CLL and Lymphoma  Diabetes Care1 day ago
[x]  

FDA Approves Gilead Sciences' (GILD) Zydelig for CLL, FL, and SLL

Visit StreetInsider.com at http://www.streetinsider.com/news.php-st=p&id=9683226 for the
 TVNewsCheck1 day ago Pharmacyclics, Inc. (PCYC) Reports Significant Data from IMBRUVICA Phase III as CLL/SLL Treatment  Crawford Financial Planning1 month ago
[x]  
Design MENA

SLL and CIBSE host Light Pollution conference in Dubai

On June 18, Chartered Institution of Building Services Engineers (CIBSE) teamed up with the Society of Light and Lighting (SLL) and launched a conference entitled Light Pollution in the Middle East in Al Barsha, Dubai. The programme included Martin ...
 Design MENA4 weeks ago SLL announces the Young Lighter of the Year 2014 shortlist  CIBSE1 month ago Links between lighting and health cannot be ignored  Lighting1 month ago New SLL President calls for greater awareness of the link between light and health  CIBSE1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less